Development of anti-pituitary antibodies (APAs) in patients treated with ipilimumab (Ipi)
| 12 weeks after Ipi N=6 | Hypo N=4 | P value | |
| Developed APAs N (%) | 0 (0) | 3 (75) | p<0.05 |
12 weeks after Ipi, group in which APAs were evaluated in sera collected 12 weeks after the initiation of Ipi in patients who did not develop pituitary immune-related adverse events; Hypo, group in which APAs were evaluated in sera collected at 2–3 weeks before the clinical onset of hypophysitis.